Profile data is unavailable for this security.
About the company
Spago Nanomedical AB (publ), formerly Spago Imaging publ AB, is a Sweden-based biotechnology company. The Company is a nanomedicine company in clinical development phase, developing products for diagnostics and treatment of life-threatening and debilitating diseases. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under Preclinical development stage. The Company’s operations are based on a patented material for the design of functional nanoparticles that accumulate physiologically in tumors, thus enabling higher precision in image diagnostics and treatment of cancer and other severe diseases.
- Revenue in SEK (TTM)437.00k
- Net income in SEK-26.55m
- Incorporated1999
- Employees7.00
- LocationSpago Nanomedical AB (publ)Scheelevagen 22LUND 223 63SwedenSWE
- Phone+46 4681188
- Websitehttps://spagonanomedical.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Larkberget AB | 252.00k | -12.15m | 43.56m | 1.00 | -- | 0.785 | -- | 172.87 | -0.6134 | -0.6134 | 0.0127 | 2.80 | 0.0038 | -- | 0.3856 | 252,000.00 | -18.32 | -13.26 | -19.12 | -13.90 | -- | -- | -4,819.84 | -66.97 | -- | -- | -- | -- | -100.00 | -- | 72.46 | -- | -- | -- |
| Acousort AB | 6.85m | -12.15m | 52.06m | 16.00 | -- | 3.19 | -- | 7.60 | -0.6493 | -0.6493 | 0.3455 | 0.7702 | 0.4536 | 0.0436 | 80.15 | -- | -80.44 | -50.20 | -98.16 | -72.34 | 98.38 | 73.10 | -177.35 | -280.44 | 6.58 | -8.94 | -- | -- | 44.67 | 6.82 | 19.40 | -- | -- | -- |
| Chosa Oncology AB | 717.00k | -6.01m | 59.17m | -- | -- | 3.67 | -- | 82.53 | -0.0766 | -0.0766 | 0.0096 | 0.2044 | 0.0382 | -- | 0.8639 | -- | -32.00 | -55.65 | -35.30 | -67.69 | 643.24 | -- | -837.66 | -792.50 | -- | -49.05 | 0.00 | -- | -39.73 | -62.56 | 59.93 | -- | -- | -- |
| Spago Nanomedical AB (publ) | 437.00k | -26.55m | 80.05m | 7.00 | -- | 2.60 | -- | 183.18 | -0.0513 | -0.0513 | 0.0008 | 0.0465 | 0.0115 | -- | 4.39 | 62,428.57 | -69.64 | -30.44 | -81.41 | -32.48 | -- | -- | -6,076.43 | -3,410.33 | -- | -- | -- | -- | -77.13 | 5.02 | 18.32 | -- | -- | -- |
| Opsy Holding AB | 6.69m | -7.86m | 81.26m | 7.00 | -- | 52.66 | -- | 12.14 | -8.55 | -8.55 | 0.705 | 0.1215 | 0.8126 | -- | 9.41 | 955,857.10 | -95.38 | -129.63 | -199.92 | -161.05 | 144.70 | -- | -117.38 | -2,431.63 | -- | -69.76 | 0.435 | -- | -- | -- | 62.94 | -- | 43.17 | -- |
| IDL Diagnostics AB (publ) | 52.19m | -39.31m | 83.85m | 22.00 | -- | 0.5604 | -- | 1.61 | -0.1706 | -0.1706 | 0.2266 | 0.6495 | 0.3263 | 6.59 | 5.26 | 2,372,364.00 | -24.58 | -29.04 | -26.98 | -31.14 | 21.53 | 1.70 | -75.32 | -157.60 | 3.29 | -- | 0.0843 | -- | 33.45 | 164.62 | 28.41 | -- | 18.85 | -- |
| Lifecare ASA | 1.73m | -117.42m | 88.51m | 28.00 | -- | -- | -- | 51.12 | -2.48 | -2.48 | 0.0379 | -0.11 | 0.0168 | -- | 0.1582 | 55,272.73 | -115.30 | -52.64 | -194.19 | -61.98 | -- | -- | -6,864.75 | -277.39 | -- | -- | 1.17 | -- | -26.10 | 36.13 | -103.52 | -- | -- | -- |
| Biosergen AB | 0.00 | -40.82m | 90.17m | 1.00 | -- | -- | -- | -- | -17.68 | -17.68 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -112.64 | -- | -- | -- |
| Coegin Pharma AB | 0.00 | -20.64m | 97.27m | 3.00 | -- | 8.35 | -- | -- | -0.7859 | -0.7859 | 0.00 | 0.4681 | 0.00 | -- | -- | 0.00 | -85.07 | -133.34 | -91.51 | -179.59 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 15.00 | -- | -- | -- |
| Glycorex Transplantation AB (publ) | 39.94m | -7.06m | 102.04m | 20.00 | -- | 2.86 | 43.37 | 2.55 | -0.0917 | -0.0917 | 0.5174 | 0.4719 | 0.7442 | 1.45 | 5.20 | 1,997,000.00 | -13.15 | -15.79 | -17.51 | -18.66 | 81.68 | 87.06 | -17.67 | -44.85 | 1.56 | -15.83 | 0.1599 | -- | 17.35 | -0.5296 | 63.97 | -- | -- | -- |
| Exact Therapeutics AS | 0.00 | -68.54m | 102.09m | 12.00 | -- | 1.59 | -- | -- | -1.40 | -1.40 | 0.00 | 1.07 | 0.00 | -- | -- | 0.00 | -108.82 | -43.50 | -168.39 | -50.76 | -- | -- | -- | -- | -- | -20.18 | 0.0052 | -- | -- | -- | -8.27 | -- | 1.47 | -- |
| Alzinova AB | 205.00k | -26.88m | 102.65m | 5.00 | -- | 0.5018 | -- | 500.75 | -0.2846 | -0.2846 | 0.0022 | 1.23 | 0.0015 | -- | 0.3254 | 41,000.00 | -19.42 | -12.21 | -20.69 | -12.85 | -5,834.15 | -- | -13,114.15 | -21,390.81 | -- | -1,794.80 | 0.0062 | -- | -88.89 | -- | -24.71 | -- | 19.48 | -- |
| Biovica International AB | 9.86m | -76.47m | 104.06m | 24.00 | -- | 0.8842 | -- | 10.55 | -0.6375 | -0.6375 | 0.0684 | 0.4241 | 0.0799 | 12.71 | 4.46 | 365,333.30 | -61.92 | -58.22 | -70.41 | -66.49 | -171.53 | -462.09 | -775.22 | -1,804.16 | 8.11 | -- | 0.0239 | -- | 18.23 | 38.83 | 29.80 | -- | -47.26 | -- |
| Alligator Bioscience AB | 514.00k | -51.35m | 106.58m | 13.00 | -- | 1.27 | -- | 207.36 | -1.09 | -1.09 | 0.0074 | 0.1566 | 0.0048 | -- | 1.98 | -- | -47.78 | -101.41 | -- | -222.85 | -- | -- | -9,990.27 | -526.56 | -- | -- | 0.8354 | -- | -99.11 | -34.77 | 78.05 | -- | 70.30 | -- |
| Abera Bioscience AB | 0.00 | -10.45m | 108.05m | 5.00 | -- | 5.60 | -- | -- | -0.5692 | -0.5692 | 0.00 | 1.04 | 0.00 | -- | -- | -- | -49.58 | -63.36 | -74.82 | -81.05 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -850.27 | -- | -- | -- |
| Annexin Pharmaceuticals AB (publ) | 0.00 | -36.89m | 110.12m | 4.00 | -- | 4.42 | -- | -- | -5.98 | -5.98 | 0.00 | 3.53 | 0.00 | -- | -- | 0.00 | -150.00 | -137.53 | -190.93 | -169.50 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 26.58 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Spago Nanomedical AB (publ)'s reporting currency: Swedish Krona SEK
0.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FCG Fonder ABas of 31 Mar 2025 | 35.02k | 0.01% |
Data from 30 Dec 2025 - 30 Dec 2025Source: FactSet Research Systems Inc.
